Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Sudewi Mukaromah Khoirunnisa, Fithria Dyah Ayu Suryanegara, Didik Setiawan & Maarten Jacobus Postma. (2024) Quality-adjusted life years for HER2-positive, early-stage breast cancer using trastuzumab-containing regimens in the context of cost-effectiveness studies: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-17.
Read now
Read now
Vakaramoko Diaby, Reem D. Almutairi, Aram Babcock, Richard K. Moussa & Askal Ali. (2021) Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews. Expert Review of Pharmacoeconomics & Outcomes Research 21:3, pages 353-364.
Read now
Read now
Livio Garattini, Alessandro Curto & Nick Freemantle. (2015) Personalized medicine and economic evaluation in oncology: all theory and no practice?. Expert Review of Pharmacoeconomics & Outcomes Research 15:5, pages 733-738.
Read now
Read now
Brett Doble, Marcus Tan, Anthony Harris & Paula Lorgelly. (2015) Modeling companion diagnostics in economic evaluations of targeted oncology therapies: systematic review and methodological checklist. Expert Review of Molecular Diagnostics 15:2, pages 235-254.
Read now
Read now
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Arja Jukkola-Vuorinen, Minna Tanner, Riitta Kokko, Johan Ahlgren, Päivi Auvinen, Outi Saarni, Leena Helle, Kenneth Villman, Paul Nyandoto, Greger Nilsson, Mika Leinonen, Vesa Kataja, Petri Bono & Henrik Lindman. (2014) Outcome of patients with HER2-positive breast cancer treated with or without adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). Acta Oncologica 53:2, pages 186-194.
Read now
Read now
György Várady, Judit Cserepes, Adrienn Németh, Edit Szabó & Balázs Sarkadi. (2013) Cell Surface Membrane Proteins as Personalized Biomarkers: Where we Stand and Where we are Headed. Biomarkers in Medicine 7:5, pages 803-819.
Read now
Read now
Mo Yang, Dhaval S Patil, Waqas Tufail & Amalia M Issa. (2013) The quality of economic studies of cancer pharmacogenomics: a quantitative appraisal of the evidence. Expert Review of Pharmacoeconomics & Outcomes Research 13:5, pages 597-611.
Read now
Read now
Jim Lee, Erik Tollefson, Matthew Daly & Edward Kielb. (2013) A generalized health economic and outcomes research model for the evaluation of companion diagnostics and targeted therapies. Expert Review of Pharmacoeconomics & Outcomes Research 13:3, pages 361-370.
Read now
Read now
Ulla Wilking, Bengt Jönsson, Nils Wilking & Jonas Bergh. (2010) Trastuzumab use in breast cancer patients in the six Health Care Regions in Sweden. Acta Oncologica 49:6, pages 844-850.
Read now
Read now
Articles from other publishers (28)
Phu Duy Pham, Muchandifunga Trust Muchadeyi & Lars Lindholm. (2023) In situ breast cancer surgeries in Sweden: lumpectomy or mastectomy?—a cost-effectiveness analysis over a 30-Year period using Markov model. Cost Effectiveness and Resource Allocation 21:1.
Crossref
Crossref
Csongor György Lengyel, Baker Shalal Habeeb, Sara Cecilia Altuna, Dario Trapani, Shah Zeb Khan & Sadaqat Hussain. 2023. Breast Cancer Research and Treatment. Breast Cancer Research and Treatment
353
368
.
Zhijia Tang & Weimin Cai. 2020. Pharmacogenomics in Precision Medicine. Pharmacogenomics in Precision Medicine
241
255
.
Ugne Sabale, Mattias Ekman, Daniel Thunström, Claire Telford & Christopher Livings. (2017) Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden. PharmacoEconomics - Open 1:4, pages 279-290.
Crossref
Crossref
Fang-Ping Xu, Kun Wang, Jie Xu, Jie Chen, Yi-Fang Zhang, Hong-Mei Wu, Ming-Hui Zhang, Xiao-Xu Long, Xin-Lan Luo, Ke-Ping Zhang, Dan-Yi Lin & Yan-Hui Liu. (2017) Impact of repeat HER2 testing after initial equivocal HER2 FISH results using 2013 ASCO/CAP guidelines. Breast Cancer Research and Treatment 166:3, pages 757-764.
Crossref
Crossref
Xavier Ghislain Léon Victor Pouwels, Bram L. T. Ramaekers & Manuela A. Joore. (2017) Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer. Breast Cancer Research and Treatment 165:3, pages 485-498.
Crossref
Crossref
Virginie Nerich, Sopany Saing, Eva Maria Gamper, Georg Kemmler, Franck Daval, Xavier Pivot & Bernhard Holzner. (2016) Cost–utility analyses of drug therapies in breast cancer: a systematic review. Breast Cancer Research and Treatment 159:3, pages 407-424.
Crossref
Crossref
Catherine Beauchemin, Marie-Ève Lapierre, Nathalie Letarte, Louise Yelle & Jean Lachaine. (2016) Use of Intermediate Endpoints in the Economic Evaluation of New Treatments for Advanced Cancer and Methods Adopted When Suitable Overall Survival Data are Not Available. PharmacoEconomics 34:9, pages 889-900.
Crossref
Crossref
Quang A. Le. (2016) Structural Uncertainty of Markov Models for Advanced Breast Cancer. Medical Decision Making 36:5, pages 629-640.
Crossref
Crossref
Yao-Shan Fan, Carmen E. Casas, Jinghong Peng, Melanie Watkins, Lynn Fan, Jennifer Chapman, Offiong Francis Ikpatt, Carmen Gomez, Wei Zhao & Isildinha M. Reis. (2016) HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline. Breast Cancer Research and Treatment 155:3, pages 457-462.
Crossref
Crossref
Elizabeth J. J. Berm, Margot de Looff, Bob Wilffert, Cornelis Boersma, Lieven Annemans, Stefan Vegter, Job F. M. van Boven & Maarten J. Postma. (2016) Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature. PLOS ONE 11:1, pages e0146262.
Crossref
Crossref
Lorena San Miguel & Frank Hulstaert. (2015) The importance of test accuracy in economic evaluations of companion diagnostics. Journal of Comparative Effectiveness Research 4:6, pages 569-577.
Crossref
Crossref
Ruth Schwarzer, Ursula Rochau, Kim Saverno, Beate Jahn, Bernhard Bornschein, Nikolai Muehlberger, Magdalena Flatscher-Thoeni, Petra Schnell-Inderst, Gaby Sroczynski, Martina Lackner, Imke Schall, Ansgar Hebborn, Karl Pugner, Andras Fehervary, Diana Brixner & Uwe Siebert. (2015) Systematic overview of cost–effectiveness thresholds in ten countries across four continents. Journal of Comparative Effectiveness Research 4:5, pages 485-504.
Crossref
Crossref
Marie-Pierre Chenard, Marie-Pierre Wissler, Noëlle Weingertner, Carole Mathelin & Jean-Pierre Bellocq. (2015) HER2 gene and protein expression status of breast carcinoma can be reliably tested on a single slide. Virchows Archiv 467:2, pages 169-175.
Crossref
Crossref
Livio Garattini, Katelijne van de Vooren & Alessandro Curto. (2015) Cost-effectiveness of trastuzumab in metastatic breast cancer: Mainly a matter of price in the EU?. Health Policy 119:2, pages 212-216.
Crossref
Crossref
Bengt Jönsson & Nils Wilking. (2014) New cancer drugs in Sweden: Assessment, implementation and access. Journal of Cancer Policy 2:2, pages 45-62.
Crossref
Crossref
Mario García Molina, Liliana Alejandra Chicaíza-Becerra, Liliana Alejandra Chicaíza-Becerra, Carlos Castañeda, Carlos Castañeda, Oscar Gamboa Garay & Oscar Gamboa Garay. (2014) ErbB2+metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country. Revista de Salud Pública 16:2, pages 270-280.
Crossref
Crossref
Bonny Parkinson, Sallie-Anne Pearson & Rosalie Viney. (2013) Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique. The European Journal of Health Economics 15:1, pages 93-112.
Crossref
Crossref
Kacey Goodrich, Billingsley Kaambwa & Hareth Al-Janabi. (2012) The Inclusion of Informal Care in Applied Economic Evaluation: A Review. Value in Health 15:6, pages 975-981.
Crossref
Crossref
Douglas M. Minot, Jesse Voss, Susan Rademacher, Toe Lwin, Jessica Orsulak, Bolette Caron, Rhett Ketterling, Aziza Nassar, Beiyun Chen & Amy Clayton. (2012) Image Analysis of HER2 Immunohistochemical Staining. American Journal of Clinical Pathology 137:2, pages 270-276.
Crossref
Crossref
Patricia R. Blank, Holger Moch, Thomas D. Szucs & Matthias Schwenkglenks. (2011)
KRAS
and
BRAF
Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective
. Clinical Cancer Research 17:19, pages 6338-6346.
Crossref
Crossref
Jeffrey S Ross. (2011) Point: Fluorescence In Situ Hybridization Is the Preferred Approach over Immunohistochemistry for Determining HER2 Status. Clinical Chemistry 57:7, pages 980-982.
Crossref
Crossref
Talia S. Foster, Jeffrey D. Miller, Mark E. Boye, Marissa B. Blieden, Risha Gidwani & Mason W. Russell. (2011) The economic burden of metastatic breast cancer: A systematic review of literature from developed countries. Cancer Treatment Reviews.
Crossref
Crossref
Stefan Vegter, Esther Jansen, Maarten J. Postma & Cornelis Boersma. (2010) Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature. Drug Development Research 71:8, pages 492-501.
Crossref
Crossref
Patricia R. Blank, Matthias Schwenkglenks, Holger Moch & Thomas D. Szucs. (2010) Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost–effectiveness analysis of different predictive assay strategies. Breast Cancer Research and Treatment 124:2, pages 497-507.
Crossref
Crossref
Shaheenah DawoodKristine BroglioAman U. BuzdarGabriel N. HortobagyiSharon H. Giordano. (2010)
Prognosis of Women With Metastatic Breast Cancer by
HER2
Status and Trastuzumab Treatment: An Institutional-Based Review
. Journal of Clinical Oncology 28:1, pages 92-98.
Crossref
Crossref
Nan Soon Wong, Benjamin O Anderson, Kei Siong Khoo, Peng Tiam Ang, Cheng Har Yip, Yen-Shen Lu, Narind Voravud, Zhi-Ming Shao & Kathleen I Pritchard. (2009) Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. The Lancet Oncology 10:11, pages 1077-1085.
Crossref
Crossref
Jeffrey S. Ross, Elzbieta A. Slodkowska, W. Fraser Symmans, Lajos Pusztai, Peter M. Ravdin & Gabriel N. Hortobagyi. (2009) The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine. The Oncologist 14:4, pages 320-368.
Crossref
Crossref